Cite
HARVARD Citation
Garcia-Campelo, R. et al. (2020). Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung cancer. pp. 62-69. [Online].